【机构调研记录】汇安基金调研百济神州

中金财经

May 11

　　证券之星消息，根据市场公开信息及5月8日披露的机构调研信息，汇安基金近期对1家上市公司进行了调研，相关名单如下：1)百济神州 (汇安基金管理有限责任公司参与公司特定对象调研&路演活动&电话会议) 　　调研纪要：百悦泽?是唯一在头对头研究中证实优于伊布替尼的BTK抑制剂，为基石性、同类最佳。2026年Q1美国收入7.66亿美元(+36%)，中国4.65亿美元(+17%)，欧洲1.91亿美元(+64%)。百悦泽?与百悦达?联合方案(ZS)有望改写一线CLL治疗模式，III期试验预计2026年底读出PFS数据。公司推进CDK4抑制剂、GPC3-4-1BB(获FDA快速通道)、PRMT5抑制剂一线拓展，并布局KRAS分子胶与DC药物。BON-110三抗增加CTLA-4臂以增强免疫激活。停止Pan-KRAS小分子项目，转向联合疗法。　　汇安基金成立于2016年，截至目前，资产管理规模(全部公募基金)415.59亿元，排名91/212；资产管理规模(非货币公募基金)415.59亿元，排名83/212；管理公募基金数138只，排名61/212；旗下公募基金经理18人，排名77/212。旗下最近一年表现最佳的公募基金产品为汇安成长优选混合A，最新单位净值为3.24，近一年增长164.06%。为证券之星据公开信息整理，由AI算法生成(网信算备310104345710301240019号)，不构成投资建议。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2634279944"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2634279944\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2634279944?lang=en_US&edition=fundamental","thumbnail":"https://static.tigerbbs.com/ http://caiji.3g.cnfol.com/colect/202605/11/20260511200946.png?op=imageView2&mode=2&width=256&height=256&quality=70&format=png","is_english":false,"pubTime":"2026-05-11 08:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2634279944","market":"hk","top_or_hot":-1,"title":"【机构调研记录】汇安基金调研百济神州","media":"中金财经","content":"<html><body><p>　　证券之星消息，根据市场公开信息及5月8日披露的机构调研信息，汇安基金近期对1家上市公司进行了调研，相关名单如下：1)<a href=\"https://laohu8.com/S/ONC\">百济神州</a> (汇安基金管理有限责任公司参与公司特定对象调研&amp;路演活动&amp;电话会议)\r\n\r\n　　调研纪要：百悦泽?是唯一在头对头研究中证实优于伊布替尼的BTK抑制剂，为基石性、同类最佳。2026年Q1美国收入7.66亿美元(+36%)，中国4.65亿美元(+17%)，欧洲1.91亿美元(+64%)。百悦泽?与百悦达?联合方案(ZS)有望改写一线CLL治疗模式，III期试验预计2026年底读出PFS数据。公司推进CDK4抑制剂、GPC3-4-1BB(获FDA快速通道)、PRMT5抑制剂一线拓展，并布局KRAS分子胶与DC药物。BON-110三抗增加CTLA-4臂以增强免疫激活。停止Pan-KRAS小分子项目，转向联合疗法。\r\n\r\n　　汇安基金成立于2016年，截至目前，资产管理规模(全部公募基金)415.59亿元，排名91/212；资产管理规模(非货币公募基金)415.59亿元，排名83/212；管理公募基金数138只，排名61/212；旗下公募基金经理18人，排名77/212。旗下最近一年表现最佳的公募基金产品为汇安成长优选混合A，最新单位净值为3.24，近一年增长164.06%。为证券之星据公开信息整理，由AI算法生成(网信算备310104345710301240019号)，不构成投资建议。            </p></body></html>","source":"zhongjincaijing_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【机构调研记录】汇安基金调研百济神州</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【机构调研记录】汇安基金调研百济神州\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-11 08:30 北京时间&nbsp;&nbsp;&nbsp;<a href=http://sc.stock.cnfol.com/gushiyaowen/20260511/32214023.shtml><strong>中金财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>证券之星消息，根据市场公开信息及5月8日披露的机构调研信息，汇安基金近期对1家上市公司进行了调研，相关名单如下：1)百济神州 (汇安基金管理有限责任公司参与公司特定对象调研&路演活动&电话会议)\n\n　　调研纪要：百悦泽?是唯一在头对头研究中证实优于伊布替尼的BTK抑制剂，为基石性、同类最佳。2026年Q1美国收入7.66亿美元(+36%)，中国4.65亿美元(+17%)，欧洲1.91亿美元(+...</p>\n\n<a href=\"http://sc.stock.cnfol.com/gushiyaowen/20260511/32214023.shtml\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260511/32214023.shtml","article_id":"2634279944","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/ http://caiji.3g.cnfol.com/colect/202605/11/20260511200946.png?op=imageView2&mode=2&width=256&height=256&quality=70&format=png"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2634279944","pubTimestamp":1778459423,"columns":[],"sourceInfo":{"source_id":"zhongjincaijing_highlight","name":"中金在线"},"weMediaInfo":null,"summary":"证券之星消息，根据市场公开信息及5月8日披露的机构调研信息，汇安基金近期对1家上市公司进行了调研，相关名单如下：1)百济神州 . 　　汇安基金成立于2016年，截至目前，资产管理规模415.59亿元，排名91/212；资产管理规模415.59亿元，排名83/212；管理公募基金数138只，排名61/212；旗下公募基金经理18人，排名77/212。旗下最近一年表现最佳的公募基金产品为汇安成长优选混合A，最新单位净值为3.24，近一年增长164.06%。","collect":0,"end_time":0,"defaultTopTitle":"cnfol.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688235":"百济神州","BK4588":"碎股","BK1500":"做空集合股","LU1251922891.USD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) ACC","ONC":"百济神州","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK4139":"生物科技","LU1303224171.USD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) INC","BK1588":"回港中概股","BK1161":"生物科技","LU1719994722.HKD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (HKD) ACC","LU1770034418.SGD":"ALL CHINA EQUITY \"A\" (SGDHDG) ACC","BK4526":"热门中概股","BK4585":"ETF&股票定投概念","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK1583":"高瓴概念","06160":"百济神州","BK0239":"医药制造","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD"},"translate_title":"[Institutional Research Record] Hui' an Fund investigates BeiGene","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688235":1.5,"ONC":1.5,"06160":1.5},"content_text":"证券之星消息，根据市场公开信息及5月8日披露的机构调研信息，汇安基金近期对1家上市公司进行了调研，相关名单如下：1)百济神州 (汇安基金管理有限责任公司参与公司特定对象调研&路演活动&电话会议)\n\n　　调研纪要：百悦泽?是唯一在头对头研究中证实优于伊布替尼的BTK抑制剂，为基石性、同类最佳。2026年Q1美国收入7.66亿美元(+36%)，中国4.65亿美元(+17%)，欧洲1.91亿美元(+64%)。百悦泽?与百悦达?联合方案(ZS)有望改写一线CLL治疗模式，III期试验预计2026年底读出PFS数据。公司推进CDK4抑制剂、GPC3-4-1BB(获FDA快速通道)、PRMT5抑制剂一线拓展，并布局KRAS分子胶与DC药物。BON-110三抗增加CTLA-4臂以增强免疫激活。停止Pan-KRAS小分子项目，转向联合疗法。\n\n　　汇安基金成立于2016年，截至目前，资产管理规模(全部公募基金)415.59亿元，排名91/212；资产管理规模(非货币公募基金)415.59亿元，排名83/212；管理公募基金数138只，排名61/212；旗下公募基金经理18人，排名77/212。旗下最近一年表现最佳的公募基金产品为汇安成长优选混合A，最新单位净值为3.24，近一年增长164.06%。为证券之星据公开信息整理，由AI算法生成(网信算备310104345710301240019号)，不构成投资建议。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}